



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-359-4005, x108

STENTYS concludes clinical trial ahead of plan

Fast enrollment underscores increasing technology adoption among 50 European hospitals in APPOSITION III study

PRINCETON, N.J., and PARIS, Feb. 1st, 2012 — **STENTYS S.A. ([STNT.PA](#))**, a medical technology company commercializing the world's first and only **Self-Apposing™ Stent** to treat **Acute Myocardial Infarction (AMI)**, announced today that the “**APPOSITION III**” clinical study successfully enrolled 1,000 patients suffering from a severe heart attack and that the final results of the examination 30 days after treatment will be presented during the upcoming EuroPCR international cardiology congress.

“Closing the study ahead of our projected timetable is a clear sign of the increasing adoption of our technology among cardiologists. The impressive interim clinical results reported two months ago should be confirmed by the final results and will prove that the Self-Apposing™ technology is *the best* solution for treating heart attack patients,” said **Gonzague Issenmann, CEO and co-founder of STENTYS**.

The STENTYS Self-Apposing™ Stent represents a major breakthrough: it solves the stent sizing dilemma that cardiologists are confronted with when treating heart attack patients with conventional stents. It “fits snugly” into the contour of a blood vessel, and its shape and diameter adapt to the anatomic changes of the coronary arteries during the post-AMI phase, avoiding a major complication of all other conventional stents: **malapposition**.

About STENTYS

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by **Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic)** and **Gonzague Issenmann**, STENTYS received CE-marking for its flagship products in 2010. Its Self-Apposing™ stent adapts to the anatomic changes of the artery in the post-infarction phase and thus prevents the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.

#####